Technology evaluation: HspE7, StressGen Biotechnologies Corp
Hunt, S.
Current Opinion in Molecular Therapeutics 3(4): 413-417
2001
ISSN/ISBN: 1464-8431 PMID: 11525566 Document Number: 530297
StressGen is developing HspE7 (SGN-00101) as a potential therapy for human papillomavirus (HPV)-associated conditions. It is a recombinant fusion protein comprising the HPV E7 antigen and the heat shock protein, hsp65, from Mycobacterium bovis. By November 2000, it was in phase III trials for HPV-related anal dysplasia [405228]. Under an aggrement formed in November 1999, the US National Cancer Institute (NCI) is carrying out clinical trials with StressGen in diseases caused by HPV [347155].